Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy

Expert Review of Obstetrics and Gynecology

Volumn 7, Issue 5, 2012, Pages 413-419

  Scarlett, Uciane K ^a   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

angiogenesis; dendritic cell; fibroblast; immunotherapy; ovarian cancer; tumor immunology; tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD40 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; BIOENGINEERING; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOREDUCTIVE SURGERY; DISEASE ACTIVITY; ENDOTHELIUM CELL; FIBROBLAST; HOST CELL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; LEUKOCYTE; LYMPHOCYTE; METASTASIS POTENTIAL; NONHUMAN; OVARY CANCER; PARACRINE SIGNALING; PERSONALIZED MEDICINE; REVIEW; TARGET CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84867525282     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.12.41     Document Type: Review

References (51)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1), 20-37 (2007).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
3. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl.), 517-523 (1993).
4. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433-443 (2010).
5. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 42(7), 918-931 (2011).
6. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
7. Burger RA, Brady MF, Bookman MA et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473-2483 (2011).
8. Perren TJ, Swart AM, Pfisterer J et al.; ICON7 Investigators. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484-2496 (2011).
9. Huarte E, Cubillos-Ruiz JR, Nesbeth YC et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 68(18), 7684-7691 (2008).
10. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69(18), 7329-7337 (2009).
11. Scarlett UK, Rutkowski MR, Rauwerdink AM et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209(3), 495-506 (2012).
12. Pedroza-Gonzalez A, Xu K, Wu TC et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 208(3), 479-490 (2011).
13. Marigo I, Bosio E, Solito S et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32(6), 790-802 (2010).
14. Conejo-Garcia JR, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat. Med. 10(9), 950-958 (2004).
15. Conejo-Garcia JR, Buckanovich RJ, Benencia F et al. Vascular leukocytes contribute to tumor vascularization. Blood 105(2), 679-681 (2005).
16. Cubillos-Ruiz JR, Engle X, Scarlett UK et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumorassociated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231-2244 (2009).
17. Cubillos-Ruiz JR, Fiering S, Conejo-Garcia Jr. Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol. 5(8), 1189-1192 (2009).
18. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia Jr. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9(2), 260-268 (2010).
19. Nagaraj S, Gabrilovich DI. Myeloidderived suppressor cells in human cancer. Cancer J. 16(4), 348-353 (2010).
20. Cubillos-Ruiz JR, Conejo-Garcia Jr. It never rains but it pours: Potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell Cycle 10(3), 368-369 (2011).
21. Cubillos-Ruiz JR, Martinez D, Scarlett UK et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 1(5), 329-338 (2010).
22. Nesbeth Y, Conejo-Garcia Jr. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin. Dev. Immunol. 2010, 139304 (2010).
23. Nesbeth Y, Scarlett U, Cubillos-Ruiz J et al. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res. 69(15), 6331-6338 (2009).
24. Nesbeth YC, Martinez DG, Toraya S et al. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol. 184(10), 5654-5662 (2010).
25. Son DS, Parl AK, Rice VM, Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol. Ther. 6(8), 1302-1312 (2007).
26. Sangaletti S, Tripodo C, Ratti C et al. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res. 70(20), 7764-7775 (2010).
27. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 8(7), 578-585 (1996).
28. Fleming JS, Beaugié CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Mol. Cell. Endocrinol. 247(1-2), 4-21 (2006).
29. Kulbe H, Chakravarty P, Leinster DA et al. Australian Ovarian Cancer Study Group. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 72(1), 66-75 (2012).
30. Zhang L, Conejo-Garcia JR, Katsaros D et al.; Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
31. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther. 5(9), 1193-1210 (2005).
32. Conejo-Garcia JR, Benencia F, Courreges MC et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells. Cancer Res. 64(6), 2175-2182 (2004).
33. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007).
34. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005).
35. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6), 1141-1149 (2009).
36. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
37. Diefenbach CS, Gnjatic S, Sabbatini P et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14(9), 2740-2748 (2008).
38. Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccinekeyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 13(14), 4170-4177 (2007).
39. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11(3), 517-525 (2012).
40. Carpenito C, Milone MC, Hassan R et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360-3365 (2009).
41. Tchou J, Wang LC, Selven B et al. Mesothelin, a novel immunotherapy target for triple-negative breast cancer. Breast Cancer Res. Treat. 133(2), 799-804 (2012).
42. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 209(2), 201-209 (2012).
43. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
44. Grossman SA, Ye X, Piantadosi S et al.; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16(8), 2443-2449 (2010).
45. Ahonen CL, Wasiuk A, Fuse S et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111(6), 3116-3125 (2008).
46. Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T-cell expansion with variable dependence on type I IFN. J. Exp. Med. 199(6), 775-784 (2004).
47. Cubillos-Ruiz JR, Baird JR, Tesone AJ et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 72(7), 1683-1693 (2012).
48. Nick AM, Stone RL, Armaiz-Pena G et al. Silencing of p130cas in ovarian carcinoma: A novel mechanism for tumor cell death. J. Natl Cancer Inst. 103(21), 1596-1612 (2011).
49. Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T-cell homing to tumors and disables immune therapy. Nat. Med. 14(1), 28-36 (2008).
50. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: Cancer and other tales. Nat. Rev. Immunol. 11(10), 702-711 (2011).
51. Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330(6005), 827-830 (2010).